Ocugen vs Outlook Therapeutics
OCGN and OTLK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCGN and OTLK compare
Ocugen is the larger company, worth 2.9 times as much as Outlook Therapeutics ($257M against $87.8M).
Outlook Therapeutics scores higher on the StockData Score (4 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCGN | OTLK |
|---|---|---|
| Size and price | ||
| Market cap | $257M | $87.8M |
| Share price | $0.757 | $0.361 |
| Change, 1 year | −36.4% | −77.0% |
| Change, 5 years | −88.3% | −98.7% |
| Beta (5Y) | −0.16 | 3.72 |
| Employees | 116 | 17 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| FCF yield | −23.8% | – |
| Growth | ||
| Revenue growth, 5Y average | 152% | – |
| Financial health | ||
| Interest coverage | −8.2× | – |
| Current ratio | 0.80 | 0.81 (better) |
| Altman Z-score | −6.09 (better) | −40.77 |
| Piotroski F-score | 0 | 1 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −62.3% |
| Shareholder yield | 0.00% (better) | −62.3% |
| Ownership | ||
| Held by institutions | 42.8% | 8.4% |
| Held by insiders | 2.4% | 28.5% |
| Insider net buying, 12 months | −$1.1M | $7.9M (better) |
| Short interest, % of float | 32.5% | 20.4% |
Go deeper
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
- OTLK stock overview
- OTLK income statement
- OTLK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.